Executive summary of Session 3 of the VALUE-Dx Regulatory/HTA/Payer EAP



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.





















Version 01 2






















































Version 01 3

Third EAP session

1.1. Meeting overview

The third session of the VALUE-Dx Expert Advisory Panel (EAP) was held virtually on the 29th of September 2021. There were five members of the EAP present.

1.2. Topics and themes discussed

1. Value-Dx progress update

An update on the status of the PRUDENCE (RCT of point of care diagnostics for enhancing the quality of antibiotic prescribing for community acquired acute respiratory tract infection in ambulatory care in Europe) and ADEQUATE trials (RCT of rapid syndromic diagnostic testing for enhancing the quality of antibiotic prescribing for community acquired acute respiratory tract infection in emergency rooms in Europe).

- 2. Findings from a mapping exercise using survey data to understand the approach to HTA, pricing and reimbursement of diagnostics across 16 countries
- 3. Policy design and its influence on the uptake of diagnostics
- 4. The sustainability of healthcare systems and whether diagnostic tests will continue to be considered of high importance
- 5. Feedback from the EAP on sessions so far

Version 01 4

